Intra-arterial infusion of labeled particles is an effective method for endoradiotherapy of tumors. In this study, we radiolabeled biodegradable HSA microspheres (mean diameter = 25 microm) with the short-lived beta-emitter 188Re available from the aluminia-based 188W/188Re generator system. After 1 h 35-40% of the relative large amount of Sn(II) chloride required for effective reduction of Re(VII) for efficient attachment to the particles is precipitated as an amorphous coat of tin hydroxid colloid on the particle surface. The final 188Re bound to the particles was found to be stable in vitro. The radiolabelling yield was > 90%. The biological half-life was > 250 h and demonstrated sufficient in vivo stability after i.v. injection in Wistar rats. Because of the attractive properties of 188Re and the uniform particle size and stability, in vivo, this new agent is an attractive candidate for endoradiotherapy of tumors after selective catheterization.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0969-8043(99)00093-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CXCR4-directed endoradiotherapy with [Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed/refractory acute myeloid leukemia.
Theranostics
January 2025
Department of Internal Medicine III, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Article Synopsis
- Despite improvements in targeted therapy for Acute Myeloid Leukemia (AML), the prognosis remains poor, particularly for patients with relapsed or refractory disease.
- Allogeneic hematopoietic stem cell transplantation (alloSCT) is the main curative option for high-risk patients, but the best conditioning approach is still uncertain for those who are chemotherapy-refractory.
- A study on seven AML patients who received CXCR4-directed endoradiotherapy (ERT) combined with total body irradiation and chemotherapy prior to alloSCT showed promising outcomes, with 6 out of 7 patients achieving response and successful engraftment, offering insights into a potentially effective treatment strategy for advanced cases.
Lu Radiolabeled Polydopamine Decorated with Fibroblast Activation Protein Inhibitor for Locoregional Treatment of Glioma.
Chembiochem
December 2024
Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610000, China.
Radionuclide therapy is expected to be a powerful tool for glioma treatment. Here, we introduced a novel nuclear nanomedicine based on polydopamine (PDA), incorporating fibroblast activation protein inhibitor (FAPI) and macrocyclic chelator (DOTA) for specific cancer targeting and Lu labeling. The synthesized nanoradiopharmaceutical, Lu-DOTA-PEG-PDA-FAPI, exhibits good stability in serum, saline and PBS over 5 days.
View Article and Find Full Text PDFDevelopment of ibuprofen-modified fibroblast activation protein radioligands to improve cancer therapy.
Eur J Med Chem
February 2025
GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China; School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China. Electronic address:
Article Synopsis
- The study focused on creating new FAP-targeting radioligands using an optimized amino acid linker and ibuprofen to enhance their effectiveness in cancer diagnosis and therapy.
- Three novel quinoline-based FAP ligands, labeled with gallium-68 and lutetium-177, showed strong binding affinity and stability, along with improved tumor accumulation in imaging studies.
- Among these ligands, [Lu]Lu-FAPI-Ibu3 demonstrated significantly better tumor-to-kidney dose ratios and longer survival in endoradiotherapy tests, positioning it as the most promising candidate for future clinical applications.
Enhancing the radionuclide theranostic concept through the radiohybrid approach.
RSC Med Chem
November 2024
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research Bautzner Landstraße 400 D-01328 Dresden Germany
Radionuclide theranostics - a fast-growing emerging field in radiopharmaceutical sciences and nuclear medicine - offers a personalised and precised treatment approach by combining diagnosis with specific and selective targeted endoradiotherapy. This concept is based on the application of the same molecule, labelled with radionuclides possessing complementary imaging and therapeutic properties, respectively. In radionuclide theranostics, radionuclide pairs consisting of the same element, such as Cu/Cu, Pb/Pb or I/I are of significant interest due to their identical chemical and pharmacological characteristics.
View Article and Find Full Text PDFEANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses.
Eur J Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Purpose: This study by the EANM radiobiology working group aims to analyze the efficacy and toxicity of targeted radionuclide therapy (TRT) using radiopharmaceuticals approved by the EMA and FDA for neuroendocrine tumors and prostate cancer. It seeks to understand the correlation between physical parameters such as absorbed dose and TRT outcomes, alongside other biological factors.
Methods: We reviewed clinical studies on TRT, focusing on the relationship between physical parameters and treatment outcomes, and applying basic radiobiological principles to radiopharmaceutical therapy to identify key factors affecting therapeutic success.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!